MKI67 and neoplasm: TNBC patients who underwent PET/CT at diagnosis mostly had proliferative biomarkers (i.e., 92.8% of patients had a grade-three tumor and 91.3% had a Ki67 ≥ 20%), meaning that even if our survival data were representative of the TNBC population, we probably did not capture all TNBCs.